Cfo4 Life Group, LLC Vertex Pharmaceuticals Inc Transaction History

Cfo4 Life Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$392.81 - $485.53 $4,713 - $5,826	12 Added 0.68%	1,786 $837,000
Q1 2024 May 06, 2024	SELL	$407.69 - $446.08 $41,584 - $45,500	-102 Reduced 5.44%	1,774 $741,000
Q4 2023 Jan 24, 2024	SELL	$343.0 - $410.68 $32,585 - $39,014	-95 Reduced 4.82%	1,876 $763,000
Q3 2023 Oct 30, 2023	SELL	$338.18 - $362.46 $14,203 - $15,223	-42 Reduced 2.09%	1,971 $685,000
Q2 2023 Aug 07, 2023	BUY	$314.42 - $351.91 $33,328 - $37,302	106 Added 5.56%	2,013 $708,000
Q1 2023 May 03, 2023	BUY	$283.23 - $323.1 $7,930 - $9,046	28 Added 1.49%	1,907 $600,000
Q4 2022 Feb 03, 2023	BUY	$285.76 - $321.48 $536,943 - $604,060	1,879 New	1,879 $542,000

1,722

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Cfo4 Life Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Cfo4 Life Group, LLC with notifications on news.